Oppenheimer Maintains Outperform on ORIC Pharmaceuticals, Lowers Price Target to $15
Portfolio Pulse from Benzinga Newsdesk
Oppenheimer analyst Matthew Biegler maintains an Outperform rating on ORIC Pharmaceuticals (NASDAQ:ORIC) but lowers the price target from $17 to $15.
August 13, 2024 | 10:06 am
News sentiment analysis
Sort by:
Ascending
NEUTRAL IMPACT
Oppenheimer analyst Matthew Biegler maintains an Outperform rating on ORIC Pharmaceuticals but lowers the price target from $17 to $15.
The Outperform rating suggests continued confidence in ORIC Pharmaceuticals' performance, but the lowered price target indicates a more cautious outlook on its short-term valuation.
CONFIDENCE 90
IMPORTANCE 70
RELEVANCE 100